Mapping the genetic–transcriptional landscape of thyroid irAEs in sintilimab therapy: toward biomarker-guided immunotoxicity prediction
This study established a genetic-transcriptional regulatory framework for sintilimab-induced thyroid irAEs and identified a candidate gene set with biomarker potential. Our findings highlighted the central role of complement-driven mechanisms, providing a foundation for precision risk prediction and targeted intervention strategies that preserve antitumor efficacy while mitigating autoimmune toxicity.
Authors
- He Su
- Bing Shang
- Yu‐Qi Feng (ORCID: https://orcid.org/0000-0003-1107-5385)
- Yafei Shi (ORCID: https://orcid.org/0000-0001-7034-8035)
- Guohui Li (ORCID: https://orcid.org/0000-0003-3235-894X)
- Mingyu Zhang (ORCID: https://orcid.org/0000-0002-2065-4365)
- Yutao Liu (ORCID: https://orcid.org/0000-0001-6477-9875)
- Wei Chen (ORCID: https://orcid.org/0000-0001-6048-1860)
- Taifeng Li
Institutions
- China Pharmaceutical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.3389/fimmu.2025.1671594
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00